RSS

Independent Data Monitoring Committee (IDMC)

Nanobiotix, a late-stage clinical nanomedicine company, has announced that the Independent Data Monitoring Committee (IDMC) has completed the interim evaluation of the Phase II/III trial results of NBTXR3 in soft tissue sarcoma. more

News